Clinical trial NCT04384835: Analysis of Sexual Bias in Type 2 Innate Lymphoid Cells (ILC2) in Asthmatic Patients
Official title: Analysis of Sexual Bias in Type 2 Innate Lymphoid Cells (ILC2) in Asthmatic Patients: Role of Androgens
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Keywords: allergy
type 2 innate lymphoid cells
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2020-05-12
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Asthma patients

Brief summary: Asthma is more common in females than in males but the difference has not been explained yet. Group 2 innate lymphoid cells (ILC2) have recently emerged as critical players in the initiation of allergic responses but their implications in the difference between males and females in terms of asthma prevalence has not been fully studied. The aim of this project is to compare the proportion of ILC2 in blood between males and females with asthma.

Detailed description: Asthma is more common in males until puberty but becomes more prevalent and more severe in females after puberty suggesting a protective action of male sex hormones. ILC2 have recently emerged as critical players in the initiation of allergic responses. The present team established that androgens, signaling through the nuclear receptor 3 C4 (NR3C4) androgen receptor (AR), negatively control ILC2 at steady state and during lung inflammation. Relevant to this application, females with asthma have more circulating ILC2 than males. The present hypothesis is that harnessing AR signaling in ILC2 may provide a new therapeutic approach to down regulate tissue resident ILC2. This project will analyze the sex bias in circulating ILC2 in female and male patients with moderate to severe asthma. In females with asthma, the team will purify circulating ILC2 from peripheral blood mononuclear cells (PBMC) and expand them in vitro using cytokines and stromal cells in the presence of AR antagonist or agonist ligands. Bulk ILC2 cultures at day 7 will used to measure the expression profile of various gene, including AR.

Eligibility criteria: Inclusion Criteria:

* Asthma according to the criteria described by Global Initiative for Asthma (GINA) guidelines
* Severe asthma according to the criteria described by the American Thoracic Society (ATS) / European Respiratory Society (ERS) guidelines (for the recruitment of severe patients)
* Mild to moderate asthma based on low or medium dose of inhaled steroids according to GINA guidelines

Exclusion Criteria:

* Asthma exacerbations defined as oral corticosteroids related to worsening respiratory symptoms within the past 4 weeks
* Pregnant women
* Breastfeeding women
* Autoimmune diseases
* Androgen medication
* Early menopause defined as the absence of menstruation for at least 1 year
* Body mass index ≥ 30 kg/m²
* Weight \<40 kg
* Oral corticotherapy for more than 3 months
* Prediction of blood volume collected (care + research)\> 80 ml or\> 150 ml over a period of 30 days if blood collection within the past 30 days
* known anemia with hemoglobin \<10 g/dl

Primary outcomes:
measure: Frequency of circulating ILC2 between gender with asthma.
timeFrame: Day 1
Secondary outcomes:
measure: Frequency of circulating ILC2 according to asthma severity.
timeFrame: Day 1
measure: Comparison of the effect of (androgenic receptor) AR ligands in a culture of ILC2.
timeFrame: Day 1
Other outcomes:
Locations:
city: Toulouse
country: France
facility: Larrey hospital
Study officials:
affiliation: University Hospital, Toulouse
name: Laurent Guilleminault, MD
role: PRINCIPAL_INVESTIGATOR
References: